Recruiting studies: Fibrolamellar Carcinoma

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A French Multicenter Observational Retrospective Study of Rare Primary Liver Cancers
Phase N/A · 40 location(s) · Federation Francophone de Cancerologie Digestive · NCT06541652 Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor Patients
Phase 1/Phase 2 · 2 location(s) · St. Jude Children's Research Hospital · NCT05468359 FusionVAC22_01: Fusion Transcript-based Peptide Vaccine Combined with Immune Checkpoint Inhibition
Phase 1 · 1 location(s) · University Hospital Tuebingen · NCT05937295 Testing the Addition of an Anti-cancer Drug, DT2216, to the Usual Chemotherapy Treatment for Relapsed or Refractory Soli
Phase 1/Phase 2 · 21 location(s) · Children's Oncology Group · NCT06620302 Nivolumab, Fluorouracil, and Interferon Alpha 2B for the Treatment of Unresectable Fibrolamellar Cancer
Phase 1/Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT04380545 Peptide Vaccine for Fibrolamellar Hepatocellular Carcinoma Patients and Other Tumor Entities Carrying the Driver Fusion
Phase 1 · 2 location(s) · University Hospital Tuebingen · NCT06789198 Agnostic Therapy in Rare Solid Tumors
Phase 2 · 8 location(s) · Instituto do Cancer do Estado de São Paulo · NCT06638931 Checkpoint Inhibition In Pediatric Hepatocellular Carcinoma
Phase 2 · 5 location(s) · Allison O'Neill, MD · NCT04134559 DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Fibrolamellar Hepat
Phase 1 · 1 location(s) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · NCT04248569 DRP-104 (Glutamine Antagonist) in Combination With Durvalumab in Patients With Advanced Stage Fibrolamellar Carcinoma (F
Phase 1/Phase 2 · 1 location(s) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · NCT06027086

Look up another condition

Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.